Glenmede Trust Co NA Cuts Stock Position in Pfizer Inc. NYSE:PFE

Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Servic… Shares in some of America’s largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Hu… Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1. Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat’s FREE daily newsletter.

Privacy Policy | No cost, no obligation to buy anything ever.Past performance is no guarantee of future results. The facts discussed here and much other information on Zacks.com might help determine whether or not it’s worthwhile paying ironfx review attention to the market buzz about Pfizer. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.

Top institutional investors of Pfizer include State Street Corp (5.13%), Wellington Management Group LLP (2.89%), Charles Schwab Investment Management Inc. (2.30%) and Geode Capital Management LLC (2.08%). Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico, Scott Gottlieb and Alexander R Mackenzie. Discover which analysts rank highest on predicting the price target of PFE. Select to analyze similar companies using key performance metrics; select up to 4 stocks. Please bear with us as we address this and restore your personalized lists. Pfizer (PFE Quick QuotePFE – Free Report) has been one of the most searched-for stocks on Zacks.com lately.

Normally $25 each – click below to receive one report FREE:

The firm has a market cap of $146.38 billion, a PE ratio of 34.91, a P/E/G ratio of 0.83 and a beta of 0.67. Pfizer Inc. has gann fan indicator a 52 week low of $24.48 and a 52 week high of $31.54. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

Analyst Price Targets

The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. At this stage, if you’re investing in Pfizer, it’s because you’re optimistic about its growth opportunities outside vaccine-related revenue. The big growth opportunity may be in oncology, especially with Pfizer investing $43 billion to acquire Seagen, which makes antibody-drug conjugates that are more targeted treatment options than chemotherapy. Through the first nine months of the year, Pfizer has generated revenue of $45.9 billion, up 2% overall. While that seems modest, it’s not a bad growth rate when you factor in a steep decline from COVID vaccine sales. Comirnaty, the company’s COVID vaccine, has generated sales of less than $2 billion, which represents a year-over-year decline of 66%.

Zacks’ 7 Best

So, you might want to look at some of the facts that could shape the stock’s performance in the near term. Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select va… Click the link below and we’ll send you MarketBeat’s list of ten stocks that will drive in any economic environment. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Compared to the Zacks Consensus Estimate of $15.19 billion, the reported revenues represent a surprise of +16.53%.

• Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company’s earnings projection.
• Pfizer’s financial health is concerning, with unsustainable dividend pa…
• Please bear with us as we address this and restore your personalized lists.
• Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children.
• It employs roughly 79,000 people and is headquartered in New York state.
• It was the first mass producer of the “miracle drug” penicillin in the 1940s and was generating more than a billion dollars in sales by the early 1970s.

There’s a fair bit of uncertainty around Pfizer’s business in both the near term and over the long haul. There’s no denying that the recent election results do appear to be weighing on investors, as Pfizer’s stock has hit a new low since then. Today, the stock is trading at a heavily discounted forward price-to-earnings multiple (based on analyst estimates) of less than 9, which suggests that investors are feeling a bit concerned about Pfizer’s future. No investment decision can be efficient without considering a stock’s valuation. Whether a stock’s current price rightly reflects the intrinsic value of the underlying business and the company’s growth prospects is an essential determinant of its future price performance.

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.

Who is the chief executive officer (CEO) of Pfizer?

The company expanded during the late 1800s and early 1900s, remaining a privately held company until June 1942, when it offered shares of its common stock to the public for the first time. It was the first mass producer of the “miracle drug” penicillin in the 1940s and was generating more than a billion dollars in sales by the early 1970s. Pfizer has become one of the biggest pharmaceutical companies in the world, with a market capitalization of $251.3 billion as of Nov. 3, 2021. During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high…

What’s happening with the Pfizer COVID-19 vaccine?

As of Aug. 9, 2021, Pfizer had 5,606,688,356 shares of voting common stock outstanding. Yes, Pfizer pays a regular quarterly cash dividend of $0.39 per share. The FDA gave the vaccine full approval on Aug. 23, 2021, after reviewing the biologics license application (BLA) submitted by Pfizer and BioNTech. It was the first COVID-19 vaccine to receive full approval from the FDA. Pfizer Inc.  PFE shares are lower on Thursday due to news that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.

Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… This instant news alert was generated review adventure capitalist: the ultimate road trip by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting.

© 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.